Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GlioPDO: Patient-Derived Organoids for Glioblastoma
NCT06781372Not yet recruiting
- Sponsor
- Policlinico Gemelli
- Start
- Apr 2025
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Single-arm trial, sponsored by Policlinico Gemelli. Primary endpoint: Histopathological PDO and tumor evaluation at 36 months. Planned start Apr 2025; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06781372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06781372.